Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > BUSINESS
BUSINESS
- Lenvima/Keytruda Combo Fails in 1st-Line Melanoma Study
April 10, 2023
- JCR, Sumitomo Sign Copromotion Pact for Izcargo in Japan
April 7, 2023
- Japan Pharma Sales Up 1.3% in FY2022: Encise
April 7, 2023
- Kissei’s ITP Med Tavalisse Now Available in Japan
April 7, 2023
- Major Renovation at Eisai’s Tsukuba Lab Completed
April 7, 2023
- Kowa Kicks Off Another PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
April 7, 2023
- MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing
April 6, 2023
- Macrocyclic Peptide Hits Milestone in Joint R&D: PeptiDream/Bayer
April 6, 2023
- Avastin Biosimilar Grabs Ovarian Cancer Nod: Nippon Kayaku/Celltrion
April 6, 2023
- Sumitomo to Combine US Subsidiaries as It Looks towards Post-Latuda Era
April 5, 2023
- Lecanemab Use at MCI Stage Might Have Larger Impact on Delaying AD Progression: Eisai
April 5, 2023
- Padcev/Keytruda Combo Wins US Accelerated Nod for First-Line Bladder Cancer: Astellas
April 5, 2023
- Xocova Nabs Fast-Track Tag in US: Shionogi
April 5, 2023
- Silgard 9 Now Available under NIP; MSD Renews Call for Cervical Cancer Prevention
April 4, 2023
- Insmed Taps Ex-Gilead Director Makoto Nakamura as New Japan Chief
April 4, 2023
- Yoshihiro Toyohara to Lead Teva Takeda from June
April 4, 2023
- Eisai to Offer Tazverik for NCC’s Patient-Proposed Study
April 4, 2023
- 19 of 41 Drug Makers Log P/B Ratio Below 1; TSE’s Quest to Boost Market Cap Not Easy
April 4, 2023
- 5 Otsuka Execs Earn 100 Million-Plus Pay in 2022: Securities Filing
April 4, 2023
- Chugai’s Annual Pay Tops 12 Million Yen for 1st Time: Securities Report
April 4, 2023
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…